

Next Generation Cancer Therapies Programme

Virtual Event, Worldwide

24 - 25 September 2024



Scientific Programme

Tuesday 24th September 2024

Listed times are in Central European Time (CEST)

- 13:00 **WELCOME TO DAY ONE**
Introduction: Steve Wedge

SESSION 1: TARGETING RAS
Session Chair: Steve Wedge
- 13:05 **Hitoshi Iikura**
Chugai Pharmaceutical Co. Ltd, Yokohama, Japan
The development of cyclic peptides and the discovery of the LUNA18 RAS inhibitor

Q&A 13:25-13:40
- 13:40 **Jan Smith**
Revolution Medicines, California, USA
Targeting the active (GTP-bound) forms of RAS

Q&A 14:00-14:15
- 14:15 **REFRESHMENT BREAK**

SESSION 2: MOLECULAR GLUES
Session Chair: Susan Critchlow
- 14:30 **Alessio Ciulli**
University of Dundee / Amphista Therapeutics, Dundee, UK
How PROTAC degraders work: Molecular recognition and design principles

Q&A 14:50 - 15:05
- 15:05 **Saverio Alberti**
Università di Messina, Messina, Italy
Proffered Paper 1: Hu2G10 antibody-drug conjugates target cleaved-activated Trop-2 in cancer cells and show therapeutic efficacy in vivo

Q&A 15:15-15:25
- 15:25 **Romi Gupta**
The University of Alabama at Birmingham, Birmingham, USA
Proffered Paper 2: ATAD2 is a driver and a therapeutic target in ovarian cancer

Q&A 15:35-15:45
- 15:45 **REFRESHMENT BREAK**

SESSION 3: TARGETING MUTANT P53
Session Chair: Mark Pearson
- 16:00 **Ecaterina E Dumbrava**

MD Anderson Cancer Centre, Texas, USA

p53 Y220C inhibitor

Q&A 16:20 - 16:35

16:35 **POSTER SPOTLIGHTS**

2 top abstracts presented as 3-minute flash talks

16:45 **TRANSITION BREAK**

17:00 **VIRTUAL POSTER SESSION**

Wednesday 25th September 2024

Listed times are in Central European Time (CEST)

14:00 **WELCOME TO DAY TWO**

SESSION 4: PROTAC DEGRADERS

Session Chair: Susan Critchlow

14:05 **Nicolas Thoma**

FMI, Switzerland

Oncogenic transcription factors – how they work (and how to get rid of them)

Q&A 14:25-14:40

14:40 **Elisa Rioja Blanco**

ETH Zurich, Zurich, Switzerland

Proffered Paper 3: Terbium-161 radioimmunotherapy as an innovative treatment for CD30+ lymphomas

Q&A 14:50 - 15:00

15:00 **REFRESHMENT BREAK**

SESSION 5: PHENOTYPIC SCREENING

Session Chair: Mark Pearson

15:15 **Nunki Hassan**

University of Sydney, Sydney, Australia

Proffered Paper 4: Targeting PAR1 for leukemic stem cell eradication: a promising new treatment strategy for blood cancers

Q&A 15:25 - 15:35

15:35 **Aimee Iberg**

Recursion, Salt Lake City, USA

Unbiased phenotypic screening to discover next generation therapies

Q&A 15:55 - 16:10

16:10 **REFRESHMENT BREAK**

SESSION 6: ANTIBODY - DRUG CONJUGATES AND REACTIVATION OF WILD-TYPE P53

Session Chair: Erica Jackson

16:25 **Puja Sapra**

SVP, Biologics Engineering and Oncology Targeted Discovery, AstraZeneca, Gaithersburg, US

The renaissance of ADC in oncology

Q&A 16:45 - 17:00

- 17:00 **Maria Ahn**
Astex Pharmaceuticals, Cambridge, UK
ASTX295: designing a bone marrow sparing MDM2-p53 inhibitor
Q&A 17:20 - 17:35
- 17:35 **DISCUSSION SESSION**
Where will the next generation of cancer therapies come from – opportunities and challenges?
Steve Wedge, Newcastle University, UK; Susan Critchlow, AstraZeneca, Cambridge, UK, Erica Jackson, Scorpion Therapeutics, Boston, USA, Mark Pearson, Boehringer-Ingelheim, Austria
- 18:00 **SUMMARY AND CLOSE**